Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed primary care physicians identify a therapy's effect on causing a statistically significant improvement in pain symptoms as the attribute that most influences their prescribing decisions in chronic low back pain (CLBP). Clinical data and interviewed thought leaders expect that Pfizer's tanezumab will have advantages in this attribute over controlled-release oxycodone (Purdue/Munipharma/Shionogi's OxyContin, generics), the sales-leading agent in the market.

The new report entitled Chronic Low Back Pain: Novel Therapies that Offer Improved Efficacy Compared with Current NSAIDs and Opioids Must Also Have Advantages in Safety and Tolerability finds that an emerging therapy that could provide a mean reduction in pain symptoms greater than or equal to 90 percent from the established baseline measure would earn a 40 percent patient share in CLBP in the United States and a 50 percent patient share in Europe, according to surveyed U.S. and European primary care physicians.

In 2008, Decision Resources' proprietary clinical gold standard for CLBP was Pfizer's Celebrex. Based on available data and expert opinion, following its approval for the indication in 2012, tanezumab will earn gold-standard status for CLBP from 2012 through 2017. Tanezumab is expected to have competitive advantages in efficacy and safety over Celebrex.

"Primary care physicians, pain specialists and thought-leading pain researchers we interviewed are highly optimistic about tanezumab's mechanism of action and believe that this emerging therapy will be extremely effective in treating CLBP," said Decision Resources Analyst Natalie Taylor, Ph.D. "Although the drug could be limited commercially because of its intravenous delivery, interviewed thought leaders suspect that its advantages in efficacy will provide pain relief for severe CLBP patients who do not respond to or cannot tolerate treatment with strong opioids."

About the Report

Chronic Low Back Pain: Novel Therapies that Offer Improved Efficacy Compared with Current NSAIDs and Opioids Must Also Have Advantages in Safety and Tolerability is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                             Decision Resources, Inc.   Christopher Comfort                            Elizabeth Marshall   781-296-2597                                   781-296-2563   ccomfort@dresources.com                        emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017

View Now